The FDA has approved Wegovy for the treatment of adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis. AACE President Scott D.…
The FDA has expanded Wegovy use to include adults with metabolic-associated steatohepatitis (MASH) and moderate to severe fibrosis, or scarring in the liver. AACE President Scott D. Isaacs, MD, FACP…
Serena Williams is opening up about her weight loss journey with GLP-1 medication Zepbound, helping to change the conversation around obesity care. AACE President Scott D. Isaacs, MD, FACP, FACE,…
“Cortisol belly” is a popular, nonmedical term used on social media to describe excess belly fat. AACE President Scott D. Isaacs, MD, FACP, FACE, explains that it is not a medical term used by…
Knee pain is a common but often overlooked symptom in individuals with diabetes. AACE President Scott D. Isaacs, MD, FACP, FACE, explains that while many patients and clinicians focus on classic…
A new JAMA Oncology study found that Individuals with obesity taking glucagon-like peptide-1 receptor agonists (GLP-1RAs) demonstrated 17% lower cancer risk compared to non-users. AACE President…
Drugmakers are racing to bring once-daily GLP-1 weight-loss pills to market, potentially offering a more convenient alternative to weekly injections. AACE President Scott D. Isaacs, MD, FACP, FACE,…
An intriguing new option is emerging for weight-loss treatment: a once-daily pill instead of weekly injections. AACE President Scott D. Isaacs, MD, FACP, FACE, explained that many patients have tried…
A recent JAMA Oncology study shows that GLP-1 medications (liraglutide, semaglutide, tirzepatide) may reduce cancer risk in adults with obesity by 17%. The greatest reductions were seen in…
Indian regulators have approved weight loss drug Ozempic for use in the Indian market. The move comes amid a raging craze around such medicines, billed as a "miracle" by some. How do weight loss…